Overview

Immuno-Oncology Market Overview:

Cancer immunotherapy, also known as immuno-oncology, is a method of treating cancer by using the body's own immune system to stop, eliminate, and control the disease. It can also help you eliminate cancer by enhancing your immune system, providing additional components to your body to enhance the immune response, and educating your body to recognize and attack specific cancer cells. In cancer immunotherapy, a variety of therapies are available, such as targeted antibodies, cancer vaccines, adoptive cell transfer, tumor-infecting viruses, checkpoint inhibitors, cytokines, and adjuvants. Using substances from living organisms as a means to treat disease, immunotherapies are a form of biotherapy (also known as biologic therapy or biological response modifier (BRM) therapy). Gene therapy is one type of immunotherapy that uses genetic engineering to boost the immune cells' ability to fight cancer. 

The immune system of the human body is in charge of removing any foreign germs or viruses that enter the body, as they may infect the body with a disease or illness over time. Cancer cells are considered foreign bodies by the body's immune system, which eliminates them. Immuno-Oncology is a scientific endeavour by scientists to produce a cancer treatment that is effective. Immuno-Oncology is a process that involves concurrently detecting and measuring many analytes such as proteins, biomolecules, growth factors, cytokines, and chemokines. To target and destroy cancer cells, immuno-oncology primarily employs the body's natural defensive mechanism. This immuno-oncology is used to investigate the dynamic interactions between cancer cells and immune cells, the complex tumour microenvironment, detecting immunoreactivity in a variety of cell-based assays to predict mode of action, and pharmacodynamics. Furthermore, immuno-oncology has a lot of potential in drug development for disorders including cancer and cardiovascular diseases. The xMAP multiplex test, for example, provides a platform for cancer biomarker assays that may be performed on plasma, serum, cultured cells, and other biological samples. The immuno-oncology was created by the American Association of Cancer Research (AACR) to aid in the investigation of acquired resistance to receptor tyrosine kinase (RTK) inhibitors. RTK is a target for therapeutic development in the fight against cancer.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Immuno-Oncology Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Immuno-Oncology Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Immuno-Oncology Market:
• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb
• Merck & Co., Inc.
• Novartis
• AstraZeneca Plc
• Pfizer Inc
• Eli Lilly and Company
• Johnson & Johnson
• Amgen Inc.
(Note: The list of the major players will be updated with the latest market scenario and trends)

Immuno-Oncology Market Segmentation:
By Product Class
• Monoclonal Antibodies
 o Naked Monoclonal Antibodies
     o Rituxan (Rituximab)
     o Avastin (Bevacizumab)
     o Herceptin (Trastuzumab)
 o Conjugated Monoclonal Antibodies
     o ADCETRIS (Brentuximab vedotin)
     o Kadcyla (Ado-trastuzumab emtansine/TDM-1)
 o Bispecific Monoclonal Antibodies
     o Blincyto (Blinatumomab)
 o Others
• Therapeutic Vaccines
 o Provenge
• Immune Checkpoint Inhibitors
 o CTLA-4 Inhibitors (Cytotoxic T-lymphocyte-associated Protein-4)
     o Yervoy (Ipilimumab)
 o PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand
     o Opdivo (Nivolumab)
     o Keytruda (Pembrolizumab)
• Others
By Major Indications
• Head & Neck Cancer
• Lung Cancer
• Melanoma
• Lymphoma
• Leukemia
• Others

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Immuno-Oncology Market Sample Video:

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Immuno-Oncology Market By Product Class, By Major Indications and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
    2.1. Research Data 
         2.1.1. Secondary Data
                2.1.1.1. Key Data from Secondary Sources
         2.1.2. Primary Data
                2.1.2.1. Key Data from Primary Sources
    2.2. Market Size Estimation 
    2.3. Market Breakdown and Data Triangulation 
    2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Immuno-Oncology Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Type Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Immuno-Oncology Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Immuno-Oncology Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Type Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Type Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Immuno-Oncology Market, By Product Class Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Monoclonal Antibodies
        7.1.1. Naked Monoclonal Antibodies
               7.1.1.1. Rituxan (Rituximab)
               7.1.1.2. Avastin (Bevacizumab)
               7.1.1.3. Herceptin (Trastuzumab)
        7.1.2. Conjugated Monoclonal Antibodies
               7.1.2.1. ADCETRIS (Brentuximab vedotin)
               7.1.2.2. Kadcyla (Ado-trastuzumab emtansine/TDM-1)
        7.1.3. Bispecific Monoclonal Antibodies
               7.1.3.1. Blincyto (Blinatumomab)
        7.1.4. Others
   7.2. Therapeutic Vaccines
        7.2.1. Provenge
   7.3. Immune Checkpoint Inhibitors
        7.3.1. CTLA-4 Inhibitors (Cytotoxic T-lymphocyte-associated Protein-4)
               7.3.1.1. Yervoy (Ipilimumab)
        7.3.2. PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand
               7.3.2.1. Opdivo (Nivolumab)
               7.3.2.2. Keytruda (Pembrolizumab)
   7.4. Others

8. Immuno-Oncology Market, By Major Indications Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Head & Neck Cancer
   8.2. Lung Cancer
   8.3. Melanoma
   8.4. Lymphoma
   8.5. Leukemia
   8.6. Others

9. North America Immuno-Oncology Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
   9.1. Introduction
   9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
        9.2.1. U.S.A
        9.2.2. Canada
        9.2.3. Mexico
   9.3. Market Size (USD Million) Forecast for North America 2022-2028

10. Latin America Immuno-Oncology Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. Brazil
          10.2.2. Venezuela
          10.2.3. Argentina
          10.2.4. Rest of Latin America
    10.3. Market Size (USD Million) Forecast for Latin America 2022-2028

11. Europe Immuno-Oncology Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Germany
          11.2.2. U.K         
          11.2.3. France
          11.2.4. Italy
          11.2.5. Spain
          11.2.6. Russia
          11.2.7. Poland
          11.2.8. Rest of Europe
    11.3. Market Size (USD Million) Forecast for Europe 2022-2028

12. Asia Pacific Immuno-Oncology Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Japan
          12.2.2. China
          12.2.3. India
          12.2.4. Australia and New Zealand
          12.2.5. ASEAN
          12.2.6. Rest of Asia Pacific
    12.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

13. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. GCC
          13.2.2. Israel
          13.2.3. South Africa
          13.2.4. Rest of MEA
    13.3. Market Size (USD Million) Forecast for MEA 2022-2028

14. Market Share Analysis and Competitive Landscape   
    14.1. Global Landscape - Key Players, Revenue and Presence
    14.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    14.3. Global Emerging Companies
    14.4. North America - Market Share Analysis and Key Regional Players
    14.5. Europe - Market Share Analysis and Key Regional Players
    14.6. Asia Pacific - Market Share Analysis and Key Regional Players
    14.7. Global Key Player - Growth Matrix

15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    15.1. F. Hoffmann-La Roche AG
          15.1.1. Company Overview
          15.1.2. Product Portfolio
          15.1.3. SWOT Analysis
          15.1.4. Financial Overview
          15.1.5. Strategic Overview
    15.2. Bristol-Myers Squibb
          15.2.1. Company Overview
          15.2.2. Product Portfolio
          15.2.3. SWOT Analysis
          15.2.4. Financial Overview
          15.2.5. Strategic Overview                         
    15.3. Merck & Co., Inc.
          15.3.1. Company Overview
          15.3.2. Product Portfolio
          15.3.3. SWOT Analysis
          15.3.4. Financial Overview
          15.3.5. Strategic Overview
    15.4. Novartis
          15.4.1. Company Overview
          15.4.2. Product Portfolio
          15.4.3. SWOT Analysis
          15.4.4. Financial Overview
          15.4.5. Strategic Overview
    15.5. AstraZeneca Plc. 
          15.5.1. Company Overview
          15.5.2. Product Portfolio
          15.5.3. SWOT Analysis
          15.5.4. Financial Overview
          15.5.5. Strategic Overview          
    15.6. Pfizer Inc.
          15.6.1. Company Overview
          15.6.2. Product Portfolio
          15.6.3. SWOT Analysis
          15.6.4. Financial Overview
          15.6.5. Strategic Overview      
    15.7. Eli Lilly and Company
          15.7.1. Company Overview
          15.7.2. Product Portfolio
          15.7.3. SWOT Analysis
          15.7.4. Financial Overview
          15.7.5. Strategic Overview
    15.8. Johnson & Johnson
          15.8.1. Company Overview
          15.8.2. Product Portfolio
          15.8.3. SWOT Analysis
          15.8.4. Financial Overview
          15.8.5. Strategic Overview 
    15.9. Amgen Inc. 
          15.9.1. Company Overview
          15.9.2. Product Portfolio
          15.9.3. SWOT Analysis
          15.9.4. Financial Overview
          15.9.5. Strategic Overview 

16. Pre and Post COVID-19 Impact
    16.1. Positive influence on the healthcare industry
    16.2. The financial disruption of the manufacturing sector
    16.3. Impact of COVID-19 on emerging companies
    16.4. Significant mandates in the healthcare regulations initiated by administrations
    16.5. The overall economic slowdown of the developing and developed nations

17. FutureWise SME Key Takeaway Points for Client

Tables

Figures